Abbott publish series of multikinase inhibitors « Kinase News

Blogroll
Tags
AstraZeneca aurora Avastin bayer Bcr-Abl bevacizumab BMS c-kit cetuximab EGFR ErbB-2 ErbB2 erbitux Exelixis Genentech GlaxoSmithKline Gleevec GSK HER1 HER2 IGF-1R Imatinib ImClone JAK2 kinase Merck-Serono Met mTOR multikinase Nexavar Novartis onyx PDGF Pfizer phase I Phase II phase iii PI3K Preclinical regulatory Research Roche sorafenib VEGF VEGFR2
Providing a resource for information on kinase inhibitors

Abbott publish series of multikinase inhibitors

Posted on June 17, 2008 by crimsoncanary

Abbott have published a series of 7-Aminopyrazolo[1,5-a]pyrimidine urea receptor tyrosine kinase inhibitors that inhibit a variety of kinases including VEGFR, PDGFR, and KDR

Filed under: kinase | Tagged: Abbott, KDR, multikinase, PDGFR, Preclinical, Research, Synthesis, VEGFR

« Biomarkers of clinical benefit associate with erlotinib treatment in NSCLC Oncothyreon initiate Phase I trial of PI3K inhibitor PX-866 for solid tumors »